The previous series designed and equipped a fixed-wing unmanned aircraft from the airframe outward, and ended at the layer that permits it to fly. This series is about a different layer entirely, the one that pays for the work and carries it to a fielded product, and it opens with the largest source of early-stage non-dilutive research funding for small companies in the United States, the Small Business Innovation Research and Small Business Technology Transfer programs. This is a practitioner series, written for the person who will actually write the proposals and manage the awards, so it favors the mechanics over the history. One idea organizes the whole of it, that the programs are non-dilutive capital staged against demonstrated reduction of risk, a staircase that carries an unproven idea up through feasibility and development to a product the government or the market will buy, with each step releasing money against the risk the previous step retired. A caution belongs at the front, the same one that opened the regulatory article of the last series, that these are United States federal programs governed by statute and agency rule, the dollar figures and percentages and deadlines change with each reauthorization and differ between agencies, and so the numbers here are current-as-of and illustrative, and the authoritative source is always the live solicitation and the current policy directive. The programs are also not permanent, as the next section shows.

A Program That Runs on Reauthorization

The Small Business Innovation Research program, usually called SBIR, was created in 1982, and the Small Business Technology Transfer program, usually called STTR, was added a decade later, but neither is permanent law. Both run on periodic reauthorization, and they lapsed when their authority expired at the end of the 2025 fiscal year before being reauthorized in 2026 through the 2031 fiscal year, a gap of several months during which no new awards could be made, a reauthorization history the Congressional Research Service surveys. That recent lapse is the clearest possible illustration of the caution above, that the program is a creature of statute whose continuation and terms are revisited by the legislature on a schedule, so an operator plans against a program that exists today rather than one guaranteed to exist unchanged tomorrow. The Small Business Administration oversees both programs and issues the policy directive that sets the common rules, while each participating agency runs its own program within that frame, which is the structure the next article surveys. The official federal portal that lists the open solicitations and the program rules is the common entry point for an applicant.

The Core Idea, Non-Dilutive and Mission-Pulled

The defining feature of the programs is that the money is non-dilutive. Unlike the venture capital or the seed money a startup might raise, an award takes no equity and imposes no dilution on the founders, so a company can fund real research and development while keeping its ownership and, as a later article will detail, substantial rights in the data it produces. The money is also mission-pulled rather than charitable, since the participating agencies fund work they need, frequently the mission-critical engineering an agency cannot buy off the shelf, the set-aside being a slice of the agencies’ external research budgets, long held near three and a fifth percent for SBIR and near half a percent for STTR, that the largest research agencies are required by statute to spend on small business. The scale is what earns the programs the description of the largest source of early-stage non-dilutive research funding in the country, since together they obligate more than four billion dollars a year across roughly four thousand awards among their participating agencies, a figure that is current-as-of and should be checked against the program’s own reporting. The consequence for the practitioner is that the programs are competitive and purposeful, the award is won by proposing work an agency wants done, and the National Science Foundation captures the spirit in the name it gives its program, America’s Seed Fund. They are competitive in the literal sense too, since a given solicitation funds a fraction of the proposals it receives, a fraction that varies sharply by agency and topic, so an applicant should expect to lose proposals and to resubmit, a discipline a later article treats.

The Three Phases

The staircase has three steps. Phase I is the feasibility study, a small and short award, on the order of one to a few hundred thousand dollars over six months to a year, whose purpose is to establish that the idea can work at all, and which advances the technology from a concept to a demonstrated principle. Phase II is the development award, an order of magnitude larger and roughly two years long, on the order of one to two million dollars, whose purpose is to build and prove a prototype, carrying the technology from a demonstrated principle to a working article. Phase III is the commercialization step, and it carries no SBIR or STTR money at all, since its purpose is to transition the result into a product the government buys through other funds or the market buys directly, supported by a special authority that lets an agency award Phase III work to the company without recompeting it. Read against the technology readiness level scale the defense and space agencies use, the phases are a ladder, Phase I lifting an idea out of the lowest levels of mere concept, Phase II carrying it through the middle levels of a validated prototype, and Phase III pushing it toward the high levels of a fielded and operational system. The whole arc is long, since months pass between a submission and an award, each funded phase runs its own six months to two years, and a gap often falls between the phases, so carrying an idea from a first Phase I proposal to a Phase III transition is a multi-year undertaking rather than a single season’s work.

SBIR Versus STTR

The two programs are siblings with one decisive difference. SBIR is a small business doing its own research, and the rules require the company to perform the bulk of the work, at least two thirds of it in Phase I and at least half in Phase II, with the principal investigator primarily employed by the company. STTR is a small business partnered with a research institution, a university, a nonprofit laboratory, or a federally funded research and development center, and the rules set a minimum split between them, the company performing at least forty percent and the institution at least thirty, with the principal investigator allowed to sit at either one. STTR therefore exists to move an idea out of a laboratory and into a company, the technology-transfer bridge its name describes, and the practical choice between the programs turns on whether the core innovation lives inside the company already or inside a research institution it must partner with.

Who Can Compete

Eligibility is narrow by design, since the programs exist to fund small businesses rather than large ones. An applicant must be a for-profit company based in the United States, more than half owned by United States citizens or permanent residents, and small by the program’s measure, which is no more than five hundred employees counting affiliates. There are exceptions and refinements, notably an authority that lets some agencies fund companies majority-owned by multiple venture, private-equity, or hedge-fund investors, which the eligibility article will treat in full, but the basic gate is a genuinely small and genuinely domestic company. The 2026 reauthorization also added a national-security dimension to eligibility, requiring agencies to screen applicants for foreign ties and other risks, so a company’s connections as well as its size and ownership now bear on whether it may be funded. The point for orientation is that the programs are not open to everyone, and the first real task of a would-be applicant, treated in its own article, is to confirm eligibility and complete the registrations before a proposal can even be submitted.

Why the Money Is Worth the Trouble

Non-dilutive capital that funds real research is rare, and that is the program’s value. A small company can develop a technology to the point where it is investable or sellable without giving up equity to do it, can build a credit of past performance with a federal customer, and can retain the rights to what it invents and the data it generates, the protection that rests on the Bayh-Dole Act and the program’s own data-rights regime. For many small innovators the programs are the only early money that is neither a loan nor a sale of ownership, which is why they are often the bridge across the gap between a research result and a product that the commercialization article calls the valley of death. The cost of that money is real and is the subject of much of this series, the effort of writing a competitive proposal, the discipline of compliant accounting, and the burden of reporting and audit, but the trade is favorable for a company whose product is genuinely an innovation an agency wants.

What the Programs Are Not

Several misunderstandings are worth dispelling at the outset. The award comes in one of two forms depending on the agency, a grant or cooperative agreement at the agencies that fund research that way, or a procurement contract at the agencies that buy it as a deliverable, a distinction that shapes the deliverables, the accounting, and the relationship, and one the next article draws out agency by agency. Either way the award is not money to be spent freely, since it is a funded research effort with defined deliverables, milestones, and oversight. It is not free money, because the proposal and the compliance cost real time and expertise, and a company that wins without a path to use the result has gained little. It is not a substitute for a customer, since Phase III, the step that actually matters commercially, needs genuine demand rather than another award. And it is not equity investment, so it neither values the company nor entitles the government to a share of it, the very feature that makes it attractive. Holding these straight keeps the program in its proper place, a tool for funding early development rather than a business model in itself.

The Series Ahead

This article is the orientation, and the rest of the series follows the practitioner’s path through the programs. The next article surveys the participating agencies and how their models differ, then come the eligibility and registration mechanics, finding a topic and reading a solicitation, and the craft of the Phase I proposal and its review. From there the series treats Phase II and the commercialization plan, Phase III and the transition problem, the data rights that are the company’s crown jewel, the money and the compliant accounting behind a cost proposal, the obligations that follow an award, and the strategy of building a portfolio of work over time. A late article surveys the international analogs for readers outside the United States, and a capstone walks a hypothetical small company taking the fixed-wing unmanned aircraft of the previous series from a Phase I feasibility study through a Phase II prototype to a Phase III transition, tying the engineering and the funding together.

Out of Scope

A few things are deliberately set aside here. The specific current dollar amounts, set-aside percentages, work-split fractions, and deadlines are given as illustrative and current-as-of, and the authoritative figures are always those in the live solicitation and the current policy directive rather than in this article. The programs of other countries are left to the dedicated analogs article later in the series. The detailed mechanics of each step, the registrations, the proposal, the budget, and the compliance, are the subjects of their own articles and are only named here. And nothing in this series is legal, financial, or tax advice, since it is an engineering-minded overview of how the programs work and not a substitute for counsel on a particular company’s situation.

Conclusion

The SBIR and STTR programs are non-dilutive capital staged against demonstrated reduction of risk, a three-step staircase that carries a small company’s idea from a feasibility study through a funded prototype to a transition into a product, with the government funding the work it needs done and the company keeping its ownership and its invention. They run on periodic reauthorization and lapsed as recently as the last fiscal year, they are open only to genuinely small and domestic companies, and they reward a real innovation with a real path to use rather than a clever proposal alone. For the small company that could build something like the aircraft of the previous series, this is the layer that pays for the building, and the articles that follow are the practitioner’s guide to actually winning and using the money.

References